• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.

ATANAPress release28.08.2023 klo 18.32
Discuss

The Swedish Knowledge-Foundation has granted SEK 12 million to the project "Advanced materials for individualized medicine and diagnostics (https://www.kks.se/article/35-miljoner-till-forskning-i-samproduktion-med-naringslivet/)". The project is coordinated by Prof. Ian Nicholls at Linnaeus University (https://lnu.se/en/research/research-projects/project-advanced-materials-for-personal-medicine-and-diagnostics/) in collaboration with Attana AB, AroCell AB, Capitainer AB, Luma Metall AB and Region Kalmar.

The aim of the project is to provide precise information about the medical conditions of individuals and groups to optimize vaccination and medical treatment. It enables individuals, patients, care providers and decision makers, as well as researchers to optimize their decisions. The project includes the entire chain from sampling, via analysis to reporting. The project's participants gather expertise from the commercial and public sectors as well as researchers and developers.

The project consists of four sub-projects:

1. Biomarkers: Cancer biomarker detection - small cell lung cancer (Project manager: Ian Nicholls).

2. Viruses: Virus-related diseases: e.g. COVID-19 and hepatitis (Project manager: Per Nilsson).

3. Bacteria: Enhanced bacterial infection diagnosis - Lyme disease & E.coli related urinary tract infections (Project manager: Sofia Somajo).

4. Tissue samples: Biosensor-based histology - glaucoma & macular degeneration (Project manager: Camilla Mohlin).

Sub-project 1-3 builds directly on Attana's immunity profile concept and sampling with Capitainer's qDBS concept. Subproject 4 is based on Attana's tissue-based biosensors.

Shortly we will publish PMs regarding each specific sub-project and its importance for Attana.

Attana's CEO Teodor Aastrup comments:

"The project strengthens our capabilities in immunity profiles and ensures the necessary expertise and funding for the further development of immunity profiles. Thereby we can allocate the necessary resources to this project and at the same time focus other resources on our regular commercial activities."